Skip to content
Review Open access

Prognostic value of baseline plasma p-tau217 for incident cognitive impairment in cognitively unimpaired cohorts: A systematic review and meta-analysis

Sep 2026 · Journal of Alzheimer's disease reports · Vol 10 · 0 citations · 25 references
Medicine

TL;DR

Higher baseline plasma p-tau217 is a prognostic factor for broadly defined incident cognitive impairment in cognitively unimpaired adults, and evaluation of p-tau217 within multivariable prognostic models and trial-enrichment strategies is supported.

Abstract

Background Plasma phosphorylated tau 217 (p-tau217) is an accessible biomarker of Alzheimer's disease pathology, but its longitudinal association with incident cognitive impairment in cognitively unimpaired adults remains uncertain. Objective To quantify the prognostic association between baseline plasma p-tau217 and subsequent incident cognitive impairment. Methods Six databases and two trial registries were searched through July 2026 for longitudinal studies enrolling cognitively unimpaired adults with baseline plasma or serum p-tau217 and subsequent mild cognitive impairment, dementia, composite cognitive impairment, or sustained Clinical Dementia Rating progression. Adjusted hazard ratios (HRs) per 1-SD higher p-tau217 were pooled using random-effects restricted maximum likelihood with Hartung–Knapp inference. Heterogeneity and 95% prediction intervals were estimated. A post hoc sensitivity analysis excluded WHIMS. Results Six reports representing 16 cohorts were eligible; four reports contributed 13 independent cohort estimates comprising 6856 participants and 1939 events. Higher baseline p-tau217 was associated with greater hazard of incident cognitive impairment (HR 1.64, 95% CI 1.40–1.91; I2 = 88.9%; τ2 = 0.0424; 95% prediction interval 1.02–2.63). Excluding WHIMS, the association persisted across 12 cohorts and 4162 participants (HR 1.53, 95% CI 1.35–1.74; I2 = 63.6%; prediction interval 1.13–2.09). Conclusions Higher baseline plasma p-tau217 is a prognostic factor for broadly defined incident cognitive impairment in cognitively unimpaired adults. However, substantial heterogeneity, clinically distinct outcome definitions, and limited independent reports preclude interpreting the pooled HR as Alzheimer-specific progression or individual-level predictive performance. Future studies should prioritize standardized outcomes, assay harmonization, and externally validated absolute-risk models. These findings support evaluation of p-tau217 within multivariable prognostic models and trial-enrichment strategies.

Read PDF

Similar papers

Open access Sep 2026

Plasma P-tau217, APOE Genotype, and the Timing of Cognitive Impairment in individuals Across Diverse Racial and Ethnic Groups: A Pooled Analysis of Prospective Cohort Studies

Findings support the use of biomarker-informed approaches to guide monitoring and therapeutic intervention in appropriately selected at-risk individuals before the onset of clinical symptoms and support the use of biomarker-informed approaches to guide monitoring and therapeutic intervention.

Yue-Xuan Xu, T. I. Gunasekaran, Yian Gu et al. · 1 citation
Open access Aug 2026

Cognitive components derived from traditional neuropsychological tests and their associations with plasma p-tau217 and p-tau181 in mild cognitive impairment: a multisite analysis.

The findings indicate that a robust four-factor cognitive structure can be identified in clinically defined MCI cohorts without prior biological selection, and the association between latent memory factors and plasma p-tau217, observed primarily in cohorts with higher biomarker burden or clearer amnestic profiles, high...

Ana S. Perez, Hugo L. Hammer, V. Andersson et al. · 0 citations
Open access Sep 2026

Plasma p-tau181 moderates the association between ten-year atherosclerotic cardiovascular disease risk and mild cognitive impairment – HABS-HD

Greater ten-year ASCVD risk was consistently associated with cognitive impairment independent of plasma AD biomarkers, with evidence that p-tau181 modifies these associations and that their magnitude varies across racial and ethnic groups.

J. Contreras, N. Ortega, Raymond Jones et al. · 0 citations
Open access Sep 2026

Astrocyte reactivity identifies p-tau217-positive individuals at elevated risk of cognitive decline across the Alzheimer’s disease continuum

It is shown that elevated plasma GFAP significantly modulates the association between p-tau217 and both cross-sectional cognitive severity and longitudinal clinical decline, and support that astrocyte reactivity is associated with greater cognitive impairment and faster clinical decline among individuals with elevated...

B. Bellaver, G. Povala, P. C. L. Ferreira et al. · 0 citations
Open access Aug 2026

Plasma p-tau217 and NfL predict incident dementia in the community

These findings support the use of blood-based biomarkers for population-level dementia risk stratification, underscore the value of combining markers to improve prognostic precision, and can aid clinicians using plasma p-tau217 or NfL in interpreting dementia risk.

A. Sunde, D. Tovar-Rios, A. Vik-Mo et al. · 0 citations
Open access Aug 2026

Association of age with clinical progression across plasma p-tau217 levels

These findings support further evaluation of age-contextualized plasma p-tau217 interpretation for prognosis and trial enrichment and support further evaluation of age-contextualized plasma p-tau217 interpretation for prognosis and trial enrichment.

R. Shi, L. Choity, S. Brodman et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.